Dasatinib is a second-generation tyrosine kinase inhibitor, which is a better antitumor agent in the clinic, with higher event-free and overall survival and lower relapse rates compared to first-generation inhibitors, while being less toxic.
Dasatinib is mainly used for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the accelerated phase, chronic phase, and acute phase (acute granulomatous and acute lymphomatous) who are refractory to, or intolerant of, treatment regimens including imatinib mesylate, and the use of the drug by the patient should always be under the guidance of a medical professional.
Dasatinib adverse reactions include headache, pleural effusion, fever, upper respiratory tract infection, lung infection, nasopharyngitis and fatigue, etc. It may also cause hematologic reactions such as pancytopenia, nausea and vomiting, abdominal pain and diarrhea and other gastrointestinal reactions.
Contraindications and precautions: Dasatinib is contraindicated in patients who are allergic to Dasatinib or allergic to any of the excipients, Dasatinib is prohibited for use in pregnancy or lactation, in addition, Dasatinib needs to be taken as a whole tablet, and cannot be broken or chewed.
The application of Dasatinib needs to be applied under the guidance of a doctor, and it is recommended to visit a hospital for a clear diagnosis and treatment.